TELA Bio, Inc. aksje
TELA
TELA Bio, Inc.
Market Cap
$40,289,528
Om TELA Bio, Inc. aksje
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene, polyglycolic acid, and polylactic-co-glycolic acid designed to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Selskapsinformasjon
19355 Malvern, United States
Analytikernes aksjeanbefalinger
Denne oversikten gir et raskt innblikk i hvordan analytikere vurderer aksjens potensial basert på deres siste analyser og kursmål.